Stanford

Melinda L. Telli, M.D.

Professor of Medicine (Oncology)

Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Womens Cancer Center**
  900 Blake Wilbur
  MC 5348
  Palo Alto, CA 94304
  Tel (650) 498-6004 **Fax** (650) 498-7237

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**
  Vanessa Murillo - Breast Cancer Program Manager
  Email vmurill0@stanford.edu

Bio

BIO

Dr. Melinda Telli is Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine, Director of the Breast Cancer Program and Associate Director of Clinical Research at the Stanford Cancer Institute and Associate Director of the Stanford Women's Cancer Center. Dr. Telli's research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Her work has focused on the validation of homologous recombination deficiency biomarkers to help identify patients with sporadic triple-negative breast cancer that may specifically derive benefit from DNA repair defect-targeted therapies. In addition to her involvement in the clinical development of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers, she has also explored the use of 'beyond BRCA' DNA repair gene mutations as potential biomarkers to select patients for PARP inhibitor therapy in the advanced disease setting.

Dr. Telli received her undergraduate degree from the University of Pennsylvania magna cum laude and medical degree from George Washington University with Distinction. She completed internship and residency in Internal Medicine at Stanford University, and then stayed at Stanford to pursue fellowship training in Medical Oncology. She has served on numerous American Society of Clinical Oncology Committees and as a Komen Scholar, Co-Chair of the ASCO Guideline Advisory Group, member of the National Comprehensive Cancer Network Breast Cancer Guideline Panel and member of the Journal of Clinical Oncology Editorial Board. Dr. Telli is the recipient of a Susan G. Komen for the Cure Translational Postdoctoral Fellowship Award (2008), American Society of Clinical Oncology Young Investigator Award (2009), Susan G. Komen for the Cure Leadership Award (2015-2026), Triple Negative Breast Cancer Foundation Hero Award (2018), Komen SF Bay Area Visionary Award (2019), and Stanford Medicine Increasing Access to Clinical Trials Star Award (2023). She has garnered multiple teaching accolades and is a repeat recipient of the Stanford Division of Oncology Teaching Award.

CLINICAL FOCUS

- Cancer > Breast Cancer
- Triple-negative breast cancer
- BRCA1 and BRCA2 mutation-associated breast cancer

- Hereditary breast cancer
- Metastatic breast cancer
- Locally advanced breast cancer
- Medical Oncology

ACADEMIC APPOINTMENTS

- Professor-Univ Med Line, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Associate Director of Clinical Research, Stanford Cancer Institute, (2025- present)
- Director, Breast Cancer Program, Stanford Cancer Institute, (2020- present)
- Associate Director, Stanford Women's Cancer Center, Stanford Cancer Institute, (2020- present)
- Leader, Breast Cancer Clinical Care Program, Stanford Medicine, (2020- present)
- Leader, Breast Cancer Clinical Research Group, Stanford Cancer Institute, (2018- present)
- Breast Oncology Protocol Review Committee Co-Chair, Stanford Cancer Institute, (2015-2018)
- Komen Scholar, Susan G. Komen for the Cure, (2015-2024)
- Breast Cancer Guidelines Panel, National Comprehensive Cancer Network, (2014- present)
- Scientific Review Committee, Stanford Cancer Institute, (2016- present)
- ASCO Breast Cancer Adjuvant Chemotherapy and Targeted Therapy Guideline Adaptation Panel, American Society of Clinical Oncology, (2015-present)
- Medical Oncology SEP Committee, American Board of Internal Medicine, (2014-2017)
- Breast Cancer Maintenance of Certification Working Group, American Society of Clinical Oncology, (2013-2014)
- Program Committee, ASCO Breast Cancer Symposium, (2010-2013)
- Scientific Program Committee, Triple Negative Breast Cancer/Cytotoxics/Local Therapy, American Society of Clinical Oncology, (2010-2013)

HONORS AND AWARDS

- Fellow of the American Society of Clinical Oncology, American Society of Clinical Oncology (2024)
- Increasing Access to Cancer Clinical Trials Star Award, Stanford Medicine (2023)
- Visionary Award, Susan G. Komen San Francisco Bay Area (2019)
- Hero Award, Triple Negative Breast Cancer Foundation (2018)
- San Francisco Bay Area Top Doctor, Medical Oncology, Castle Connolly (2017-2023)
- Komen Leadership Award, Susan G. Komen for the Cure (2015-2024)
- Champion Award, Triple Step Toward the Cure (2015)
- Career Catalyst Research Award, Susan G. Komen for the Cure (2012)
- New Investigator Award, Stanford Cancer Institute (2011)
- Oncology Division Teaching Award, Stanford University School of Medicine (2010, 2012, 2013, 2014)
- Young Investigator Award, American Society of Clinical Oncology (2009)
- Fellowship Award, Susan G. Komen for the Cure (2008)
- Merit Award, American Society of Clinical Oncology (2008)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Editorial Board Member, Journal of Clinical Oncology (2017 - 2024)
- Co-Chair, American Society of Clinical Oncology Guideline Advisory Group (2021 - 2025)
- Program Committee, AACR San Antonio Breast Cancer Symposium (2022 - 2024)
- Member, NRG Oncology Breast Committee (2023 - present)
- Institutional PI, ECOG-ACRIN Research Group (2022 - present)

PROFESSIONAL EDUCATION

- Board Certification: Internal Medicine, American Board of Internal Medicine (2024)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2024)
- B.A., University of Pennsylvania , Biology, with Distinction (1996)
- M.D., George Washington University , Medicine, with Distinction (2002)
- Residency, Stanford University , Internal Medicine (2005)
- Fellowship, Stanford University , Medical Oncology (2008)
- Board Certification, American Board of Internal Medicine , Internal Medicine (2015)
- Board Certification, American Board of Internal Medicine , Medical Oncology (2018)

COMMUNITY AND INTERNATIONAL WORK

- Susan G. Komen for the Cure
- Facing Our Risk of Cancer Empowered (FORCE), Tampa, Florida
- Bay Area Cancer Connections, Palo Alto, CA
- Triple Step Toward the Cure, Mill Valley, CA

LINKS

- Get a Second Opinion: https://stanfordhealthcare.org/second-opinion/overview.html

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My research focuses on the development of novel therapies for the treatment of triple-negative and hereditary breast cancer and I run multiple clinical trials focused in these areas for patients with locally advanced and metastatic breast cancer. Specifically, my work has focused on the validation of homologous recombination deficiency biomarkers to help identify patients with sporadic triple-negative breast cancer that may derive benefit from DNA repair-targeted treatment strategies. In addition to my involvement in the clinical development of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers, I have also explored the use of ‘beyond BRCA’ DNA repair gene mutations as potential biomarkers to select patients for PARP inhibitor therapy in the advanced disease setting. My Komen funded work is exploring the intersection between host anti-tumor immunity and BRCAness in triple-negative breast cancer and strategies to enhance response and overcome resistance to immunotherapy using a direct intratumoral approach in metastatic TNBC. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.

CLINICAL TRIALS

- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer, Recruiting
- Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer, Recruiting
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer, Recruiting

- (VELA) Study of BLU-222 in Advanced Solid Tumors, Not Recruiting
- 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy, Not Recruiting
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors, Not Recruiting
- A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors., Not Recruiting
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer, Not Recruiting
- A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer, Not Recruiting
- A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study), Not Recruiting
- A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer, Not Recruiting
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer, Not Recruiting
- A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer, Not Recruiting
- A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer, Not Recruiting
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study), Not Recruiting
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer, Not Recruiting
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer, Not Recruiting
- A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC), Not Recruiting
- A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130), Not Recruiting
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy, Not Recruiting
- A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors, Not Recruiting
- A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer, Not Recruiting
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer, Not Recruiting
- A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery, Not Recruiting
- A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors, Not Recruiting
- A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer, Not Recruiting
- A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer, Not Recruiting
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer., Not Recruiting
- An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer, Not Recruiting
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy, Not Recruiting
- Development of Vitamin D as a Therapy for Breast Cancer - Phase 2, Not Recruiting
- Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer, Not Recruiting
- Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer, Not Recruiting

- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer, Not Recruiting
- Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease, Not Recruiting
- Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women, Not Recruiting
- Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC, Not Recruiting
- Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors, Not Recruiting
- M6620 First in Human Study, Not Recruiting
- Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer, Not Recruiting
- Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer, Not Recruiting
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer, Not Recruiting
- PALbociclib CoLlaborative Adjuvant Study, Not Recruiting
- Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab, Not Recruiting
- Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer, Not Recruiting
- Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors, Not Recruiting
- S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo, Not Recruiting
- Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer, Not Recruiting
- Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI, Not Recruiting
- Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer, Not Recruiting
- Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756), Not Recruiting
- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors, Not Recruiting
- Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug, Not Recruiting
- T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial, Not Recruiting
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A), Not Recruiting
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B), Not Recruiting
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C), Not Recruiting
- Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Not Recruiting
- Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer, Not Recruiting
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer, Not Recruiting
- Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC, Not Recruiting
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer, Not Recruiting
- Vitamin D and Breast Cancer: Does Weight Make a Difference?, Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Oncology (Fellowship Program)

Publications

PUBLICATIONS

- **Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.** *Nature medicine*

  Mittendorf, E. A., Assaf, Z. J., Harbeck, N., Zhang, H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., Ferrario, C., Punie, et al

  2025

- **Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.** *Nature medicine*

  Cardoso, F., O'Shaughnessy, J., Liu, Z., McArthur, H., Schmid, P., Cortes, J., Harbeck, N., Telli, M. L., Cescon, D. W., Fasching, P. A., Shao, Z., Loirat, D., Park, et al

  2025

- **Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.** *The oncologist*

  Litton, J. K., Beck, J. T., Jones, J. M., Andersen, J., Blum, J. L., Mina, L. A., Brig, R., Danso, M., Yuan, Y., Abbattista, A., Noonan, K., Niyazov, A., Chakrabarti, et al

  2023

- **A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.** *Nature cancer*

  Gruber, J. J., Afghahi, A., Timms, K., DeWees, A., Gross, W., Aushev, V. N., Wu, H., Balcioglu, M., Sethi, H., Scott, D., Foran, J., McMillan, A., Ford, et al

  2022

- **Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

  Telli, M. L., Nagata, H., Wapnir, I. L., Acharya, C., Zablotsky, K. E., Fox, B. A., Bifulco, C. B., Jensen, S. M., Ballesteros-Merino, C., Le, M. H., Pierce, R. H., Browning, E., Hermiz, et al

  2021

- **Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.** *Lancet (London, England)*

  Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., Ferrario, C., Punie, K., Penault-Llorca, et al

  2020; 396 (10257): 1090-1100

- **BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?** *The Lancet. Oncology*

  Telli, M. L.

  2020

- **Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.** *JAMA oncology*

  Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., Wahner-Hendrickson, A. E., Forero, A., Anders, C., Wulf, G. M., Dillon, P., Lynce, F., Zarwan, et al

  2019

- **Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

  Telli, M. L., Chu, C. n., Badve, S. S., Vinayak, S. n., Silver, D. P., Isakoff, S. J., Kaklamani, V. n., Gradishar, W. n., Stearns, V. n., Connolly, R. M., Ford, J. M., Gruber, J. J., Adams, et al

  2019

- **A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E. M., Mina, L. A., Balmaña, J., Fasching, P. A., Hurvitz, S. A., Wardley, A. M., Chappey, C., Hannah, et al
  2018

- **Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., Chang, P., Schackmann, E. A., Hartman, A., Ford, J. M., Telli, M. L.
  2017

- **Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.** *Clinical cancer research*
  Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., Isakoff, S. J., Ryan, P. D., Greene-Colozzi, et al
  2016; 22 (15): 3764-3773

- **Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity** *NATURE MEDICINE*
  Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S., Sharma, A., Holmstrom, A., Chang, A. C., Coronado, M. J., Ebert, A. D., Knowles, J. W., Telli, M. L., Witteles, et al
  2016; 22 (5): 547-556

- **Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.** *Journal of clinical oncology*
  Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., Timms, K., Abkevich, V., Schackmann, E. A., Wapnir, I. L., Carlson, R. W., Chang, P., Sparano, et al
  2015; 33 (17): 1895-1901

- **Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer** *JOURNAL OF CLINICAL ONCOLOGY*
  Telli, M. L.
  2013; 31 (29): 3613-5

- **PARP inhibitors in cancer: moving beyond BRCA** *LANCET ONCOLOGY*
  Telli, M. L.
  2011; 12 (9): 827-828

- **Breast Cancer, Version 4.2026** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., Chen, N., Chew, H., Dang, et al
  2026; 24 (7)

- **Vepdegestrant, a proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus atirmociclib (ATI) in ER+/HER2-advanced breast cancer (ABC): TACTIVE-K phase 1b/2 results.**
  Telli, M. L., Ruiz-Borrego, M., Yonemori, K., Zhao, Y., Jhaveri, K. L., Wang, S., Patnaik, A., Frenel, J., Xu, P., Tran, L., Lonning, S., Berkowitz, N. C., Zhang, et al
  LIPPINCOTT WILLIAMS & WILKINS.2026

- **Results of phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors**
  Rodon, J., Gruber, J. J., Telli, M. L., Hendifar, A., Kim, J. W., Bhardwaj, S., Sharma, P., Thakkar, D., Boyd-Kirkup, J., Kennedy, E.
  AMER ASSOC CANCER RESEARCH.2026

- **Multiscale profiling of tyrosine kinase inhibitor cardiotoxicity reveals mechanosensitive ion channel PIEZO1 as cardioprotective.** *Science translational medicine*
  Manhas, A., Liu, Y., Noishiki, C., Wu, D., Tripathi, D., Mirza, S., Thomas, D., Liu, L., Guha, A., Nguyen, P. K., Chen, I. Y., Chitalia, V., Cheng, et al
  2025; 17 (829): eadv9403

- **Interim analysis of giredestrant (GIRE) plus inavolisib (INAVO) in MORPHEUS breast cancer (BC): A phase Ib/II study of GIRE treatment (rx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/ metastatic BC (LA/mBC)**
  Rugo, H. S., Serrano, C., Jung, K. H., Telli, M. L., Sonnenblick, A., Gal-Yam, E. N., Zhu, J., Collier, A. E., Sheikh, A., Bader, U. K., Ngo, H., Schwab, R., Bermejo, et al

ELSEVIER.2025

- **Breast Cancer, Version 5.2025 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., Chen, N., Chew, H., Dang, et al
  2025; 23 (11): 426-436

- **Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast Cancer.** *Cancer reports (Hoboken, N.J.)*
  Nagpal, S., Nguyen, K. S., Bertrand, S., Cunanan, K. M., Padda, S. K., Pagtama, J. Y., Tisch, A. H., Coffey, G., Thomas, R. P., Sledge, G. W., Gruber, J., Telli, M. L., Pegram, et al
  2025; 8 (9): e70330

- **Impact of timing and breastfeeding on postpartum breast cancer diagnostic patterns and outcomes.** *Breast cancer research and treatment*
  Klebaner, D., Park, N., Stone, K., Riaz, F., Crowe, S., Telli, M., Marquez, C., Horst, K.
  2025

- **A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death.** *NPJ breast cancer*
  Noor, H., Zheng, Y., Mantz, A. B., Zhou, R., Kozlov, A., DeMartini, W. B., Chen, S. T., Okamoto, S., Ikeda, D. M., Telli, M. L., Kurian, A. W., Ford, J. M., Vinayak, et al
  2025; 11 (1): 79

- **A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression.** *Cancer research*
  Zhao, Y., Andoh, T., Charles, F., Reddy, P., Paul, K., Goar, H., Durdana, I., Golder, C. J., Hardy, A. N., Juntilla, M. M., Yang, S. R., Lin, C. Y., Sagiv-Barfi, et al
  2025

- **Deciphering VISTA immunoreceptor mechanisms to target VISTA plus triple-negative breast cancers**
  Gruber, J., Zhao, Y., Andoh, T., Charles, F., Durdana, I., Reddy, P., Paul, K., Goar, H., Golder, C., Juntilla, M., Peng, Y., Ford, J., Kurian, et al
  AMER ASSOC CANCER RESEARCH.2025

- **Sociodemographic Factors Associated with Adjuvant Chemotherapy Receipt in Stage I Triple Negative Breast Cancer (TNBC)**
  Thompson, C., Riaz, F., Satoyoshi, M., Cunanon, K., Kurian, A., Telli, M. L.
  AMER ASSOC CANCER RESEARCH.2025: P51123

- **Integration of Novel Antibody-Drug Conjugates in Advanced HER2-low, Hormone Receptor-positive and Triple-negative Breast Cancer**
  Obajimi, K., Rosenthal, K., Tolaney, S. M., Telli, M. L., Jhaveri, K., Quill, T.
  AMER ASSOC CANCER RESEARCH.2025: P21010

- **Sociodemographic Factors Associated with Use of Adjuvant Therapy in Stage I Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer**
  Riaz, F., Thompson, C., Satoyoshi, M., Cunanan, K., Bhatt, A., Kurian, A., Telli, M. L.
  AMER ASSOC CANCER RESEARCH.2025: P31121

- **Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+BRCA-mutated breast cancer with molecular residual disease after definitive therapy**
  Turner, N., Pimentel, I., Cescon, D., Iwata, H., Janni, W., Lacko, A., Loibl, S., Rugo, H., Bertelli, G., Ishiguro, H., Sukor, S., Ahola, T., Kurzeder, et al
  AMER ASSOC CANCER RESEARCH.2025

- **Spatially defining T-cell clonal evolution in post-neoadjuvant breast cancer and association with molecular residual disease**
  Ransohoff, J., Carleton, M. A., Barroso, S., Bean, G., Maltos, A., Ford, J., Duran, G., Khodadoust, M., Telli, M. L., Alizadeh, A. A., Kurtz, D. M.
  AMER ASSOC CANCER RESEARCH.2025

- **NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.**
  Valero, V., Tang, G., Rastogi, P., Geyer, C. E., Colangelo, L. H., Kengla, A., Irvin, W., Socoteanu, M. P., Abraham, J., Esparaz, B. T., Alguire, K. B., Flaherty, L. E., Jatoi, et al
  LIPPINCOTT WILLIAMS & WILKINS.2025: LBA509

- **New Treatment Approaches for Triple-Negative Breast Cancer.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*

Riaz, F., Gruber, J. J., Telli, M. L.
2025; 45 (3): e481154

- **Enhanced spatial detection of post-neoadjuvant breast cancer minimal residual disease by tissue-based Cancer Personalized Profiling by Deep Sequencing**
  Ransohoff, J., Carleton, M. A., Barroso, S., Bean, G., Maltos, A., Ford, J., Duran, G., Khodadoust, M., Telli, M. L., Alizadeh, A. A., Kurtz, D. M.
  AMER ASSOC CANCER RESEARCH.2025
- **Association of germline homologous recombination deficiency mutations with HER2 status conversion from negative to positive following neoadjuvant chemotherapy in breast cancer.**
  Bergstrom, C. P., Troxell, M., Caswell-Jin, J., Bean, G., Allison, K. H., Telli, M. L.
  LIPPINCOTT WILLIAMS & WILKINS.2025: 1034
- **Impact of timing of diagnosis and breastfeeding on postpartum breast cancer outcomes.**
  Klebaner, D., Park, N., Marquez, C., Stone, K., Crowe, S., Riaz, F., Telli, M. L., Horst, K. C.
  LIPPINCOTT WILLIAMS & WILKINS.2025: e12537
- **Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer.** *Breast cancer research and treatment*
  Beck, A. S., Earley, M., Troxell, M., Tsai, J., Telli, M. L., Wapnir, I. L.
  2025
- **High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer**
  Gottlieb, A. P., Baker, G. J., Lin, J., Pastorello, R., Chen, Y., Vallius, T., Davis, J., Yapp, C., Church, S. E., Miller, E., Farkkila, A., Vinayak, S., Telli, et al
  AMER ASSOC CANCER RESEARCH.2025
- **Defining spatial molecular residual disease by personalized tumor tissue profiling**
  Ransohoff, J. D., Carleton, M. A., Barroso, S., Phillips, N., Maltos, A., Bean, G., Goldstein, J., Gunaratne, C., Hosoya, H., Duran, G., Khodadoust, M., Ford, J., Tibshirani, et al
  AMER ASSOC CANCER RESEARCH.2025
- **Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.** *Clinical breast cancer*
  Jhaveri, K., Anders, C. K., Bardia, A., Bhave, M., Chien, A. J., Krop, I., Traina, T. A., Abdou, Y., Basho, R., Conlin, A. K., Esteva, F. J., Fox, K. R., Gadi, et al
  2025
- **VISTA-induced tumor suppression by a four amino acid intracellular motif.** *bioRxiv : the preprint server for biology*
  Zhao, Y., Andoh, T., Charles, F., Reddy, P., Paul, K., Goar, H., Durdana, I., Golder, C., Hardy, A., Juntilla, M. M., Yang, S. R., Lin, C. Y., Sagiv-Barfi, et al
  2025
- **Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., Chen, N., Chew, H., Dang, et al
  2024; 22 (5): 331-357
- **Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.** *Breast cancer (Tokyo, Japan)*
  Telli, M. L., Litton, J. K., Beck, J. T., Jones, J. M., Andersen, J., Mina, L. A., Brig, R., Danso, M., Yuan, Y., Symmans, W. F., Hopkins, J. F., Albacker, L. A., Abbattista, et al
  2024
- **TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER plus /human epidermal growth factor receptor 2 (HER2)-advanced breast cancer**
  Telli, M. L., Gawryletz, C. D., Wei, M., Patnaik, A., Lu, D. R., Mazzoletti, M., Valota, O., Parmar, S. S., Tan, W., Mukohara, T.
  LIPPINCOTT WILLIAMS & WILKINS.2024

- **Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Freedman, R. A., Caswell-Jin, J. L., Hassett, M., Somerfield, M. R., Giordano, S. H.
  2024: JCO2400886

- **Predicting outcomes in locally advanced breast cancer through profiling post-neoadjuvant tissue-based minimal residual disease**
  Ransohoff, J., Carleton, M., Birk, A., Bean, G., Telli, M., Alizadeh, A., Ford, J., Duran, G., Khodadoust, M., Kurtz, D.
  AMER ASSOC CANCER RESEARCH.2024

- **Interim analysis of giredestrant plus inavolisib in MORPHEUS Breast Cancer: a Phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer**
  Rugo, H., Gion, M., Hernando, C., Jung, K., Oliveira, M., Telli, M., Vidal, G., Vatandoust, S., Zhu, J., Schwab, R., Ngo, H., Ferreira, E., Collier, et al
  AMER ASSOC CANCER RESEARCH.2024

- **Tumor-Infiltrating Lymphocytes and Breast Cancer Mortality in Racially and Ethnically Diverse Participants of the Northern California Breast Cancer Family Registry**
  Ransohoff, J., Miller, I., Koo, J., Joshi, V., Kurian, A., Allison, K., John, E., Telli, M.
  AMER ASSOC CANCER RESEARCH.2024

- **Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER- positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer**
  Hurvitz, S., Schott, A., Ma, C., Nanda, R., Zahrah, G., Hunter, N., Tan, A., Telli, M., Mesias, J., Jeselsohn, R., Munster, P., Zhi, E., Duperret, et al
  AMER ASSOC CANCER RESEARCH.2024

- **Molecular characterization and therapeutic approach for VISTA plus triple-negative breast cancers**
  Zhao, Y., Charles, F., Lipchik, A., Peng, Y., Ford, J., Telli, M., Zhang, S., Kurian, A., Snyder, M., Gruber, J.
  AMER ASSOC CANCER RESEARCH.2024

- **Interim analysis of giredestrant plus inavolisib in MORPHEUS Breast Cancer: a Phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer**
  Rugo, H., Gion, M., Hernando, C., Jung, K., Oliveira, M., Telli, M., Vidal, G., Vatandoust, S., Zhu, J., Schwab, R., Ngo, H., Ferreira, E., Collier, et al
  AMER ASSOC CANCER RESEARCH.2024

- **Tumor-Infiltrating Lymphocytes and Breast Cancer Mortality in Racially and Ethnically Diverse Participants of the Northern California Breast Cancer Family Registry**
  Ransohoff, J., Miller, I., Koo, J., Joshi, V., Kurian, A., Allison, K., John, E., Telli, M.
  AMER ASSOC CANCER RESEARCH.2024

- **Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER- positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer**
  Hurvitz, S., Schott, A., Ma, C., Nanda, R., Zahrah, G., Hunter, N., Tan, A., Telli, M., Mesias, J., Jeselsohn, R., Munster, P., Zhi, E., Duperret, et al
  AMER ASSOC CANCER RESEARCH.2024

- **Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Burstein, H. J., DeMichele, A., Fallowfield, L., Somerfield, M. R., Henry, N. L.
  2024; 42 (12): 1450-1453

- **Tumor-Infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California breast cancer family registry.** *JNCI cancer spectrum*
  Ransohoff, J. D., Miller, I., Koo, J., Joshi, V., Kurian, A. W., Allison, K. H., John, E. M., Telli, M. L.
  2024

- **A radiogenomic approach for triple-negative breast cancer risk stratification**
  Noor, H., Zheng, Y., Mantz, A., Zhou, R., Kozlov, A., DeMartini, W. B., Chen, S., Okamoto, S., Ikeda, D., Mattonen, S., Napel, S., Telli, M. L., Sledge, et al
  AMER ASSOC CANCER RESEARCH.2024

- **Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)**

Harbeck, N., Barrios, C., Zhang, A., Saji, S., Jung, K., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M., Boileau, J., Punie, K., Dieterich, et al
KARGER.2024: 30

- **Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations.** *Stem cell research*
  Zhang, M., Venkateshappa, R., Li, A., Fowler, M. B., Telli, M. L., Wu, J. C.
  2023; 73: 103246

- **Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031**
  Harbeck, N., Duan, C., DuPree, K., Chang, C., Barrios, C. H., Zhang, H. A., Saji, S., Jung, K. H., Telli, M. L., Hermoso, M., Chui, S., Dieterich, M., Mittendorf, et al
  ELSEVIER.2023: S1149-S1150

- **KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer**
  Cardoso, F., McArthur, H. L., Schmid, P., Cortes, J., Harbeck, N., Telli, M. L., Cescon, D. W., O'Shaughnessy, J., Fasching, P., Shao, Z., Loirat, D., Park, Y. H., Fernandez, et al
  ELSEVIER.2023: S1260-S1261

- **Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.** *NPJ breast cancer*
  Turner, N. C., Laird, A. D., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E. M., Mina, L. A., Balmaña, J., Fasching, P. A., Hurvitz, S. A., Hopkins, J. F., Albacker, et al
  2023; 9 (1): 81

- **Generation of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA2 variants.** *Stem cell research*
  Zhang, M., Liu, W., Li, A., Htet, M. H., Yu, R., Telli, M. L., Wu, J. C.
  2023; 72: 103219

- **Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan** *CURRENT PROBLEMS IN CANCER: CASE REPORTS*
  Testa, S., Dickerson, J. C., Telli, M.
  2023; 11

- **Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.** *Breast cancer research and treatment*
  Lenz, L., Neff, C., Solimeno, C., Cogan, E. S., Abramson, V. G., Boughey, J. C., Falkson, C., Goetz, M. P., Ford, J. M., Gradishar, W. J., Jankowitz, R. C., Kaklamani, V. G., Marcom, et al
  2023

- **A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors**
  Ahnert, J., Gruber, J., Telli, M. L., Mita, M. M., Mita, A. C., Kim, J. W., Villalona-Calero, M., Patel, M., Yadav, S. S., Sharma, P., Haber, T., Lauren, J., Seet, et al
  LIPPINCOTT WILLIAMS & WILKINS.2023

- **A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.**
  Ahnert, J., Gruber, J., Telli, M. L., Mita, M. M., Mita, A. C., Kim, J. W., Villalona-Calero, M., Patel, M., Yadav, S. S., Sharma, P., Haber, T., Symons, J., Seet, et al
  LIPPINCOTT WILLIAMS & WILKINS.2023: TPS2664

- **Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer.** *Nature communications*
  Ransohoff, J. D., Ritter, V., Purington, N., Andrade, K., Han, S., Liu, M., Liang, S. Y., John, E. M., Gomez, S. L., Telli, M. L., Schapira, L., Itakura, H., Sledge, et al
  2023; 14 (1): 2053

- **ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study**
  Schott, A. F., Hurvitz, S., Ma, C., Hamilton, E., Nanda, R., Zahrah, G., Hunter, N., Tan, A. R., Telli, M., Mesias, J., Jeselsohn, R., Munster, P., Lu, et al
  AMER ASSOC CANCER RESEARCH.2023

- **NCCN Guidelines Insights: Breast Cancer, Version 4.2023.** *Journal of the National Comprehensive Cancer Network : JNCCN*

Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, H. J., Chew, H., Dang, C., Elias, A. D., Giordano, et al

2023; 21 (6): 594-608

- **Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.** *JAMA oncology*

  Yap, T. A., Bardia, A., Dvorkin, M., Galsky, M. D., Beck, J. T., Wise, D. R., Karyakin, O., Rubovszky, G., Kislov, N., Rohrberg, K., Joy, A. A., Telli, M. L., Schram, et al

  2022

- **Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.** *JAMA oncology*

  Schram, A. M., Colombo, N., Arrowsmith, E., Narayan, V., Yonemori, K., Scambia, G., Zelnak, A., Bauer, T. M., Jin, N., Ulahannan, S. V., Colleoni, M., Aftimos, P., Donoghue, et al

  2022

- **Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.** *Breast cancer research and treatment*

  Gupta, T., Vinayak, S., Telli, M.

  2022

- **TRIAL IN PROGRESS: A PHASE 1 FIRST-IN-HUMAN STUDY OF HMBD-002, AN IGG4 MONOCLONAL ANTIBODY TARGETING VISTA, AS A MONOTHERAPY AND COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES**

  Haber, T., Symons, J., Dharmadhikari, B., Mueller, T., Thakkar, D., Rodon, J., Gruber, J., Telli, M., Mita, M., Mita, A., Patel, M., Wang, D., Kim, et al

  BMJ PUBLISHING GROUP.2022: A655

- **Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.** *Annals of oncology : official journal of the European Society for Medical Oncology*

  Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A. C., Arnedos, M., Balmaña, et al

  2022

- **Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.** *JCO oncology practice*

  Freedman, R. A., Graff, S. L., Somerfield, M. R., Telli, M. L., Wolff, A. C., Giordano, S. H.

  2022; 18 (7): 516-519

- **Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

  Henry, N. L., Somerfield, M. R., Dayao, Z., Elias, A., Kalinsky, K., McShane, L. M., Moy, B., Park, B. H., Shanahan, K. M., Sharma, P., Shatsky, R., Stringer-Reasor, E., Telli, et al

  2022: JCO2201063

- **Harnessing artificial intelligence to automate delineation of volumetric breast cancers from magnetic resonance imaging to improve tumor characterization.**

  Zhou, R., Kozlov, A., Chen, S., Okamoto, S., Ikeda, D. M., DeMartini, W., Kurian, A. W., Sledge, G. W., Telli, M. L., Lee, K., Mantz, A. B., Itakura, H.

  LIPPINCOTT WILLIAMS & WILKINS.2022

- **Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.**

  Timms, K., Lenz, L., Cogan, E. S., Mayer, E. L., Kaklamani, V. G., Stearns, V., Abramson, V. G., Falkson, C., Jankowitz, R., Marcom, P., Tung, N. M., Gradishar, W., Ford, et al

  LIPPINCOTT WILLIAMS & WILKINS.2022

- **Radiomic features quantifying pixel-level characteristics of breast tumors from magnetic resonance imaging predict risk factors in triple-negative breast cancer.**

  Mantz, A. B., Zhou, R., Kozlov, A., DeMartini, W., Chen, S., Okamoto, S., Ikeda, D. M., Mattonen, S. A., Napel, S., Alkim, E., Sledge, G. W., Kurian, A. W., Liu, et al

  LIPPINCOTT WILLIAMS & WILKINS.2022

- **Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.** *NPJ breast cancer*

Telli, M. L., Tolaney, S. M., Shapiro, G. I., Middleton, M., Lord, S. R., Arkenau, H. T., Tutt, A., Abramson, V., Dean, E., Haddad, T. C., Wesolowski, R., Ferrer-Playan, J., Goddemeier, et al

2022; 8 (1): 45

- **Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*

  Dixon-Douglas, J., Loibl, S., Denkert, C., Telli, M., Loi, S.

  2022; 42: 1-13

- **Durable responses with intratumoral electroporation of plasmid interleukin-12 plus pembrolizumab in patients with advanced triple-negative breast cancer: Cohort 1 update from KEYNOTE-890**

  Telli, M. L., Wapnir, I., Devitt, B., Cuff, K., Soliman, H., Vinayak, S., Canton, D. A., Twitty, C. G., Xie, S., Lu, Y., Bannavong, D., O'Keeffe, B., Aung, et al

  AMER ASSOC CANCER RESEARCH.2022

- **Trial in progress: Phase 2 study of intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVO™) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (KEYNOTE-890/OMS-I141)**

  Telli, M., Devitt, B., Cuff, K., Vinayak, S., Nanda, R., Montero, A. J., Hui, R., Canton, D. A., Twitty, C., Xie, S., Bannavong, D., O'Keeffe, B., Aung, et al

  AMER ASSOC CANCER RESEARCH.2022

- **High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer**

  Guerriero, J. L., Baker, G. J., Lin, J., Chen, Y., Pastorello, R., Vallius, T., Davis, J., Yapp, C., Church, S. E., Miller, E., Farkkila, A., Vinayak, S., Telli, et al

  AMER ASSOC CANCER RESEARCH.2022

- **ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy**

  Turner, N. C., Cescon, D. W., Loibl, S., Janni, W., Rugo, H., Balmana, J., Crowley, C., Chung, J., Fucli, G., Hofstatter, E., Frenkl, T., Telli, M. L.

  AMER ASSOC CANCER RESEARCH.2022

- **Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR plus breast cancer (M-HR plus BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC)**

  Hurvitz, S. A., Boni, V., Comen, E., Im, S., Jung, K., Kim, S., Lee, K., Loi, S., Rugo, H. S., Sonnenblick, A., Telli, M. L., DuPree, K., Fasso, et al

  AMER ASSOC CANCER RESEARCH.2022

- **A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS)**

  Wapnir, I., Marquez, C., Stone, K., Allison, K., DeMartini, W., Salem, C., Tsai, J., West, R., McMillan, A., Telli, M., Horst, K.

  AMER ASSOC CANCER RESEARCH.2022

- **Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

  Meric-Bernstam, F., Tannir, N. M., Lliopoulos, O., Lee, R. J., Telli, M. L., Fan, A. C., DeMichele, A., Haas, N. B., Patel, M. R., Harding, J. J., Voss, M. H., Owonikoko, T. K., Carthon, et al

  2022

- **Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*

  Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, H. J., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, et al

  2022; 20 (6): 691-722

- **Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) plus entinostat (entino) in MORPHEUS-HR plus breast cancer (M-HR plus BC)**

  Sonnenblick, A., Im, S., Lee, K. S., Tan, A., Telli, M., Shachar, S., Tchaleu, F., Cha, E., DuPree, K., Nikanjam, M., Shemesh, C., Xu, J., Zhang, et al

  ELSEVIER.2021: S479

- **Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.** *Annals of oncology : official journal of the European Society for Medical Oncology*

Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., Xu, B., Wardley, A., Kaen, D., Andrade, L., Semiglazov, V., Reinisch, M., Patel, et al

2021; 32 (8): 994-1004

- **A Phase 1 Dose-Escalation and Expansion Study of Telaglenastat in Patients With Advanced or Metastatic Solid Tumors.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

  Harding, J. J., Telli, M., Munster, P., Voss, M. H., Infante, J. R., DeMichele, A., Dunphy, M., Le, M. H., Molineaux, C., Orford, K., Parlati, F., Whiting, S. H., Bennett, et al

  2021

- **Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.** *The New England journal of medicine*

  Tutt, A. N., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., Domchek, S. M., Gelmon, K. A., Hollingsworth, et al

  2021; 384 (25): 2394-2405

- **Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.** *NPJ breast cancer*

  Vahdat, L. T., Schmid, P., Forero-Torres, A., Blackwell, K., Telli, M. L., Melisko, M., Mobus, V., Cortes, J., Montero, A. J., Ma, C., Nanda, R., Wright, G. S., He, et al

  2021; 7 (1): 57

- **A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer.**

  Gruber, J., Gross, W., McMillan, A., Ford, J. M., Telli, M. L.

  LIPPINCOTT WILLIAMS & WILKINS.2021

- **Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.**

  Litton, J., Beck, J., Jones, J. M., Andersen, J., Blum, J., Mina, L. A., Brig, R., Danso, M. A., Yuan, Y., Abbattista, A., Noonan, K., Chakrabarti, J., Czibere, et al

  LIPPINCOTT WILLIAMS & WILKINS.2021

- **Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.**

  Telli, M. L., Litton, J., Beck, J., Jones, J. M., Andersen, J., Mina, L. A., Brig, R., Danso, M. A., Yuan, Y., Symmans, W., Abbattista, A., Noonan, K., Mata, et al

  LIPPINCOTT WILLIAMS & WILKINS.2021

- **Updates in HER2-Positive and Triple-Negative Breast Cancers** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*

  Telli, M. L., Gradishar, W. J.

  2021; 19 (5.5): 605-609

- **Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

  Denduluri, N., Somerfield, M. R., Chavez-MacGregor, M., Comander, A. H., Dayao, Z., Eisen, A., Freedman, R. A., Gopalakrishnan, R., Graff, S. L., Hassett, M. J., King, T. A., Lyman, G. H., Maupin, et al

  2021; 39 (6): 685-693

- **Genomic analysis from the talazoparib beyond BRCA clinical trial: Homologous recombination (HR) deficiency scores, loss-of-heterozygosity and mutations in non-BRCA1/2 mutant tumors with other HR mutations**

  Gruber, J. J., Afghahi, A., Hatton, A., Gross, W., Foran, J., McMillan, A., Ford, J. M., Telli, M. L.

  AMER ASSOC CANCER RESEARCH.2021

- **Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients**

  Crosby, E. J., Nagata, H., Telli, M. L., Acharya, C. R., Wapnir, I., Zablotsky, K., Browning, E., Hermiz, R., Svenson, L., Bannavong, D., Malloy, K., Canton, D. A., Twitty, et al

  AMER ASSOC CANCER RESEARCH.2021

- **NCCN Guidelines Insights: Breast Cancer, Version 4.2021.** *Journal of the National Comprehensive Cancer Network : JNCCN*

  Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Goldstein, et al

  2021; 19 (5): 484-493

- **INTRATUMORAL PLASMID IL-12 EXPANDS CD8+T CELLS AND INDUCES A CLINICALLY VALIDATED CXCR3 SIGNATURE IN TRIPLE-NEGATIVE BREAST CANCER**
  Crosby, E., Nagata, H., Telli, M., Acharya, C., Wapnir, I., Zablotsky, K., Browning, E., Hermiz, R., Svenson, L., Bannavong, D., Malloy, K., Canton, D., Twitty, et al
  BMJ PUBLISHING GROUP.2020: A472

- **IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab plus chemo in early triple-negative breast cancer (TNBC)**
  Saji, S., Mittendorf, E., Harbeck, N., Zhang, H., Barrios, C. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., Ferrario, C., Punie, K., Llorca, et al
  ELSEVIER.2020: S1243

- **IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab plus chemotherapy in early triple-negative breast cancer (TNBC)**
  Harbeck, N., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., Ferrario, C., Punie, K., Penault-Llorca, et al
  ELSEVIER.2020: S1144

- **Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.**
  Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., Kurian, A. W., Telli, M. L.
  AMER SOC CLINICAL ONCOLOGY.2020

- **KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for High-Risk, Early-Stage, ER+/HER2-Breast Cancer**
  Hirshfield, K., Cardoso, F., Bardia, A., Andre, F., Cescon, D., McArthur, H., Telli, M., Loi, S., Cortes, J., Schmid, P., Harbeck, N., Denkert, C., Jackisch, et al
  SPRINGER.2020: S288

- **A randomized phase II study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS)**
  Wapnir, I., DeMartini, W., Allison, K., Stone, K., Dirbas, F., Marquez, C., Ikeda, D., Pal, S., Tsai, J., Yang, R., West, R., McMillan, A., Telli, et al
  AMER ASSOC CANCER RESEARCH.2020

- **Clinical indications of PARP1 inhibitors and other targets**
  Telli, M. L.
  AMER ASSOC CANCER RESEARCH.2020

- **JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts**
  Yap, T. A., Konstantinopoulos, P., Telli, M. L., Saraykar, S., Beck, J., Galsky, M. D., Abraham, J., Wise, D. R., Khasraw, M., Rubovszky, G., Dvorkin, M., Joy, A. A., Opyrchal, et al
  AMER ASSOC CANCER RESEARCH.2020

- **Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/ OMS-I141)**
  Telli, M. L., Wapnir, I., Devitt, B., Cuff, K., Soliman, H., Vinayak, S., Canton, D. A., Twitty, C., Foerter, K., Joshi, R.
  AMER ASSOC CANCER RESEARCH.2020

- **Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Goldstein, et al
  2020; 18 (4): 452–78

- **Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis**
  Fernandez-Penas, P., Carlino, M., Atkinson, V., Telli, M., Joshi, R., Thomas, S., Tsai, K., Roberts-Thomson, R., Haydon, A., Mant, A., Van Hagen, T., Cuff, K., Devitt, et al
  BMC.2019

- **KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2-breast cancer**

Cardoso, F., Bardia, A., Andre, F., Cescon, D. W., McArthur, H., Telli, M., Loi, S., Cortes, J., Schmid, P., Harbeck, N., Denkert, C., Jackisch, C., Jia, et al

ELSEVIER.2019

- **Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations**

  Turner, N. C., Laird, A. D., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E., Mina, L. A., Balmana, J., Fasching, P. A., Hurvitz, S. A., Albacker, L. A., Frampton, et al

  OXFORD UNIV PRESS.2019: 108-+

- **Human-induced Pluripotent Stem Cell-derived Cardiomyocytes as a Model for Trastuzumab-Induced Cardiac Dysfunction**

  Kitani, T., Ong, S., Lam, C. K., Rhee, J., Zhang, J. Z., Oikonomopoulos, A., Ma, N., Tian, L., Lee, J., Telli, M. L., Witteles, R. M., Sharma, A., Sayed, et al

  LIPPINCOTT WILLIAMS & WILKINS.2019

- **Induced Pluripotent Stem Cell-Based Cancer Vaccines.** *Frontiers in immunology*

  Ouyang, X., Telli, M. L., Wu, J. C.

  2019; 10: 1510

- **Induced Pluripotent Stem Cell-Based Cancer Vaccines** *FRONTIERS IN IMMUNOLOGY*

  Ouyang, X., Telli, M. L., Wu, J. C.

  2019; 10

- **Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer** *CIRCULATION*

  Kitani, T., Ong, S., Lam, C., Rhee, J., Zhang, J. Z., Oikonomopoulos, A., Ma, N., Tian, L., Lee, J., Telli, M. L., Witteles, R. M., Sharma, A., Sayed, et al

  2019; 139 (21): 2451–65

- **Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.**

  Gruber, J., Afghahi, A., Hatton, A., Scott, D., McMillan, A., Ford, J. M., Telli, M. L.

  AMER SOC CLINICAL ONCOLOGY.2019

- **KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.**

  Cardoso, F., Bardia, A., Andre, F., Cescon, D. W., McArthur, H. L., Telli, M. L., Loi, S., Cortes, J., Schmid, P., Harbeck, N., Denkert, C., Jackisch, C., Jia, et al

  LIPPINCOTT WILLIAMS & WILKINS.2019

- **An open label, multicenter phase II study combining imprime PGG (PGG) with pembrolizumab (P) in previously treated metastatic triple-negative breast cancer (mTNBC).**

  O'Day, S., Borges, V. F., Chmielowski, B., Rao, R. D., Abu-Khalaf, M. M., Stopeck, A., Nikolinakos, P., Telli, M. L., Xie, B., Shaheen, M. F., Mattson, P., Gargano, M., Cox, et al

  AMER SOC CLINICAL ONCOLOGY.2019

- **NCCN Guidelines Updates: Breast Cancer.** *Journal of the National Comprehensive Cancer Network : JNCCN*

  Telli, M. L., Gradishar, W. J., Ward, J. H.

  2019; 17 (5.5): 552-555

- **CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.**

  Meric-Bernstam, F., Lee, R. J., Carthon, B., Iliopoulos, O., Mier, J., Patel, M. R., Tannir, N. M., Owonikoko, T., Haas, N. B., Voss, M., Harding, J. J., Srinivasan, R., Shapiro, et al

  AMER SOC CLINICAL ONCOLOGY.2019

- **NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC)**

  Litton, J., Symmans, F., Gogineni, K., Saltzman, M., Telli, M. L., Usha, L., Chakrabarti, J., Tudor, I. C., Quek, R. W., Czibere, A.

  CHURCHILL LIVINGSTONE.2019: S73-S74

- **Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way.** *Annals of oncology : official journal of the European Society for Medical Oncology*

Telli, M. L., Vinayak, S.
2019

- **Breast Cancer, Version 3.2018 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Goetz, M. P., Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., Farrar, W. B., Giordano, S. H., Goldstein, et al
  2019; 17 (2): 119–26

- **Durability of clinical benefit with niraparib plus pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA: (TOPACIO/Keynote-162)**
  Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., Hendrickson, A., Forero, A., Anders, C., Wulf, G., Dillon, P., Lynce, F., Zarwan, et al
  AMER ASSOC CANCER RESEARCH.2019

- **A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC)**
  Litton, J., Symmans, F., Gogineni, K., Saltzman, M., Telli, M. L., Usha, L., Chakrabarti, J., Tudor, I. C., Quek, R. G., Czibere, A.
  AMER ASSOC CANCER RESEARCH.2019

- **Spatial mapping of the immune microenvironment in primary triple-negative breast cancer (TNBC) and association with neoadjuvant therapy response**
  Telli, M. L., Vinayak, S., Khododoust, M. S., Gruber, J. J., Ford, J. M., Sanchez, P., Banayan, N., Azimi, S., Tumeh, P. C., Newman, A. M., Alizadeh, A. A.
  AMER ASSOC CANCER RESEARCH.2019

- **A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer**
  Telli, M. L., Wapnir, I., Vinayak, S., Chang, J., Alemany, C., Twitty, C., Gargosky, S.
  AMER ASSOC CANCER RESEARCH.2019

- **Intratumoral tavokinogene telseplasmid and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer**
  Telli, M. L., Zablotsky, K., Le, M. H., Canton, D., Browning, E., Bannavong, D., Gargosky, S., Wapnir, I.
  AMER ASSOC CANCER RESEARCH.2019

- **Human Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Breast Cancer Patients.** *Circulation*
  Kitani, T. n., Ong, S. G., Lam, C. K., Rhee, J. W., Zhang, J. Z., Oikonomopoulos, A. n., Ma, N. n., Tian, L. n., Lee, J. n., Telli, M. L., Witteles, R. M., Sharma, A. n., Sayed, et al
  2019

- **Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer.** *Journal of oncology practice*
  Scott, D. n., Friedman, S. n., Telli, M. L., Kurian, A. W.
  2019: JOP1900221

- **NCCN Guidelines Insights: Breast Cancer, Version 3.2018.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Goetz, M. P., Gradishar, W. J., Anderson, B. O., Abraham, J. n., Aft, R. n., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C. n., Elias, A. D., Farrar, W. B., Giordano, S. H., Goldstein, et al
  2019; 17 (2): 118–26

- **Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.** *European journal of cancer (Oxford, England : 1990)*
  Hurvitz, S. A., Quek, R. G., Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E., Mina, L. A., Balmaña, J., Fasching, P. A., Bhattacharyya, H., Hannah, et al
  2018; 104: 160-168

- **Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy** *JOURNAL OF CLINICAL ONCOLOGY*
  Cruz, C., Llop-Guevara, A., Garber, J. E., Arun, B. K., Perez Fidalgo, J. A., Lluch, A., Telli, M. L., Fernandez, C., Kahatt, C., Galmarini, C. M., Soto-Matos, A., Alfaro, V., Perez de la Haza, et al
  2018; 36 (31): 3134-+

- **A four-gene decision tree signature classification of triple-negative breast cancer: Implications for targeted therapeutics.** *Molecular cancer therapeutics*
  Quist, J., Mirza, H., Cheang, M. C., Telli, M. L., O'Shaughnessy, J., Lord, C. J., Tutt, A. N., Grigoriadis, A.
  2018

- **Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy** *CLINICAL BREAST CANCER*
  Kozak, M. M., Jacobson, C. E., von Eyben, R., Walck, E., Pollom, E. L., Telli, M., Horst, K. C.
  2018; 18 (5): E1077–E1085

- **Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Cruz, C., Llop-Guevara, A., Garber, J. E., Arun, B. K., Perez Fidalgo, J. A., Lluch, A., Telli, M. L., Fernandez, C., Kahatt, C., Galmarini, C. M., Soto-Matos, A., Alfaro, V., Perez de la Haza, et al
  2018: JCO2018786558

- **Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Bardia, A., Parton, M., Kümmel, S., Estévez, L. G., Huang, C. S., Cortés, J., Ruiz-Borrego, M., Telli, M. L., Martin-Martorell, P., López, R., Beck, J. T., Ismail-Khan, R., Chen, et al
  2018: JCO2017748392

- **Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Kozak, M. M., Jacobson, C. E., von Eyben, R., Pollom, E. L., Telli, M., Horst, K. C.
  2018; 16 (7): 845–50

- **VISTA immune checkpoint deregulation in human triple-negative breast cancer**
  Gruber, J. J., Juntilla, M. M., Yang, S., Geller, B., Jager, N., Lin, C., Lipchik, A. M., Chen, J., Ram, A., Vinayak, S., Telli, M. L., West, R. B., Ford, et al
  AMER ASSOC CANCER RESEARCH.2018

- **Intratumoral plasmid IL-12 and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer (TNBC)**
  Telli, M. L., Zablotsky, K., Gargosky, S. E., Twitty, C. G., Wapnir, I. L.
  AMER ASSOC CANCER RESEARCH.2018

- **Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer** *CLINICAL CANCER RESEARCH*
  Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., Seto, T., Thompson, C. A., Rigdon, J., Telli, M. L., Badve, S. S., Curtis, C. N., West, et al
  2018; 24 (12): 2851–58

- **Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Denduluri, N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S. L., Hassett, M. J., Holloway, J. N., Hurria, A., King, T. A., Lyman, G. H., Partridge, A. H., Somerfield, M. R., Trudeau, et al
  2018: JCO2018788604

- **Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin plus /- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.**
  Telli, M. L., Metzger, O., Timms, K., Evans, B., Vogel, D., Wei, H., Jones, J., Wenstrup, R. J., McKee, M. D., Sullivan, D., Fallstrom, M., Maag, D., Ansell, et al
  AMER SOC CLINICAL ONCOLOGY.2018

- **TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial**
  Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M. M., McCann, G., Tan, A. R., Hendrickson, A., Forero-Torres, A., Anders, C. K., Wulf, G. M., Dillon, P. M., Lynce, F., Zarwan, et al
  AMER SOC CLINICAL ONCOLOGY.2018

- **Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.** *Breast cancer research and treatment*
  Telli, M. L., Stover, D. G., Loi, S., Aparicio, S., Carey, L. A., Domchek, S. M., Newman, L., Sledge, G. W., Winer, E. P.
  2018

- **Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

  Kornblum, N., Zhao, F., Manola, J., Klein, P., Ramaswamy, B., Brufsky, A., Stella, P. J., Burnette, B., Telli, M., Makower, D. F., Cheema, P., Truica, C. I., Wolff, et al

  2018: JCO2017769331

- **Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).**

  Tannir, N. M., Fan, A. C., Lee, R. J., Carthon, B., Iliopoulos, O., Mier, J., Patel, M. R., Meric-Bernstam, F., DeMichele, A., Voss, M., Harding, J. J., Srinivasan, R., Shapiro, et al

  AMER SOC CLINICAL ONCOLOGY.2018

- **Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer**

  Kalinsky, K., Harding, J. J., DeMichele, A., Infante, J. R., Gogineni, K., Owonikoko, T. K., Isakoff, S., Iliopoulos, O., Patel, M. R., Munster, P., Telli, M. L., Jenkins, Y., Fiji, et al

  AMER ASSOC CANCER RESEARCH.2018

- **ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 1 dose expansion cohort (NCT02157792)**

  Telli, M. L., Lord, S., Dean, E., Abramson, V., Arkenau, H., Murias, C., Becerra, C., Tang, R., Penney, M. S., Pollard, J., Conboy, G., Fields, S. Z., Shapiro, et al

  AMER ASSOC CANCER RESEARCH.2018

- **Assessing treatment response in triple-negative breast cancer from quantitative image analysis in perfusion magnetic resonance imaging.** *Journal of medical imaging (Bellingham, Wash.)*

  Banerjee, I. n., Malladi, S. n., Lee, D. n., Depeursinge, A. n., Telli, M. n., Lipson, J. n., Golden, D. n., Rubin, D. L.

  2018; 5 (1): 011008

- **Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy.** *Clinical breast cancer*

  Kozak, M. M., Jacobson, C. E., von Eyben, R. n., Walck, E. n., Pollom, E. L., Telli, M. n., Horst, K. C.

  2018

- **Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer** *Breast Cancer Research and Treatment*

  Telli, M. L., Stover, D., Loi, S., Aparicio, S., Carey, L. A., Domchek, S. M., Newman, L., Sledge, G. W., Winer, E. P.

  2018: in press

- **Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update** *Journal of Clinical Oncology*

  Denduluri , N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S., Hassett, M., Holloway, J., Hurria, A., King, T., Lyman, G., Partridge, A., Somerfield, M., Trudeau, et al

  2018: In press

- **Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.** *Breast cancer research and treatment*

  Telli, M. L., Hellyer, J. n., Audeh, W. n., Jensen, K. C., Bose, S. n., Timms, K. M., Gutin, A. n., Abkevich, V. n., Peterson, R. N., Neff, C. n., Hughes, E. n., Sangale, Z. n., Jones, et al

  2018; 168 (3): 625–30

- **Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*

  Gradishar, W. J., Anderson, B. O., Balassanian, R. n., Blair, S. L., Burstein, H. J., Cyr, A. n., Elias, A. D., Farrar, W. B., Forero, A. n., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Isakoff, et al

  2018; 16 (3): 310–20

- **Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

  Afghahi, A. n., Purington, N. n., Han, S. S., Desai, M. n., Pierson, E. n., Mathur, M. B., Seto, T. n., Thompson, C. A., Rigdon, J. n., Telli, M. L., Badve, S. S., Curtis, C. n., West, et al

  2018

- **Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.** *Annals of oncology : official journal of the European Society for Medical Oncology*

  Han, H. S., Diéras, V., Robson, M., Palácová, M., Marcom, P. K., Jager, A., Bondarenko, I., Citrin, D., Campone, M., Telli, M. L., Domchek, S. M., Friedlander, M., Kaufman, et al

  2017

- **Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

  Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E. P., Naughton, M. J., Goetz, M. P., Russell, C., Tripathy, D., Cobleigh, M., Forero, et al

  2017

- **Vitamin D supplementation decreases serum 27-hydroxycholesterol and expression of CYP27A1 in tumors of breast cancer patients**

  Going, C., Alexandrova, L., Lau, K., Yeh, C., Telli, M., Jensen, K., Feldman, D., Pitteri, S.

  AMER ASSOC CANCER RESEARCH.2017

- **Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2^{mut}) screening and response monitoring to neratinib in metastatic breast cancer (MBC)**

  Ma, C., Bose, R., Gao, F., Freedman, R., Telli, M., Kimmick, G., Winer, E., Naughton, M., Goetz, M., Russell, C., Tripathy, D., Cobleigh, M., Forero, et al

  AMER ASSOC CANCER RESEARCH.2017

- **Association of a four-gene decision tree signature with response to platinum-based chemotherapy in patients with triple negative breast cancer.**

  Quist, J., Mirza, H., Cheang, M. U., Telli, M. L., Lord, C. J., Tutt, A., Grigoriadis, A.

  AMER SOC CLINICAL ONCOLOGY.2017

- **Antitumor activity of trabectedin and lurbinectedin in germline BRCA2 carriers with metastatic breast cancer (MBC) as compared to BRCA1 carriers: Analysis of two phase II trials.**

  Gelpi, J., Lubinski, J., Arun, B., Byrski, T., Telli, M. L., Isakoff, S. J., Fernandez, C., Lardelli, P., Kahatt, C., Soto-Matos, A., Delaloge, S.

  AMER SOC CLINICAL ONCOLOGY.2017

- **Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).**

  Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E., Mina, L. A., Gelpi, J., Fasching, P. A., Hurvitz, S. A., Wardley, A. M., Chappey, C., Verret, et al

  AMER SOC CLINICAL ONCOLOGY.2017

- **Outstanding Questions in the Clinical Management of Triple-Negative Breast Cancer.** *Journal of oncology practice*

  Gruber, J. J., Telli, M. L.

  2017; 13 (5): 305-307

- **NCCN Guidelines Insights: Breast Cancer, Version 1.2017.** *Journal of the National Comprehensive Cancer Network*

  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Isakoff, et al

  2017; 15 (4): 433-451

- **Circulating tumor DNA and burden of disease in breast cancer**

  Hoffman, A., Aleshin, A., Banks, K., Talasaz, A., Eltoukhy, H., Telli, M., Wapnir, I.

  SPRINGER.2017: 304–5

- **Exploiting Homologous Recombination Deficiency in TNBC** *CURRENT BREAST CANCER REPORTS*

  Aleshin, A., Telli, M. L.

  2017; 9 (1): 52–59

- **A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale** *FUTURE ONCOLOGY*

  Isakoff, S. J., Puhalla, S., Domchek, S. M., Friedlander, M., Kaufman, B., Robson, M., Telli, M. L., Dieras, V., Han, H. S., Garber, J. E., Johnson, E. F., Maag, D., Qin, et al

  2017; 13 (4): 307-320

- **Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V plus TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer**

  Dieras, V., Han, H. S., Robson, M. E., Palacova, M., Marcom, P. K., Jager, A., Bondarenko, I., Citrin, D., Campone, M., Telli, M. L., Domchek, S. M., Friedlander, M., Kaufman, et al

  AMER ASSOC CANCER RESEARCH.2017

- **Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study**

  Han, H. S., Dieras, V., Robson, M. E., Palacova, M., Marcom, P. K., Jager, A., Bondarenko, I., Citrin, D., Campone, M., Telli, M. L., Domchek, S. M., Friedlander, M., Man, et al

  AMER ASSOC CANCER RESEARCH.2017

- **Reply to L. Del Mastro and A. Prat.** *Journal of clinical oncology*

  Denduluri, N., Somerfield, M. R., Eisen, A., Holloway, J. N., Hurria, A., King, T. A., Lyman, G. H., Partridge, A. H., Telli, M. L., Trudeau, M. E., Wolff, A. C.

  2017: JCO2016709758-?

- **Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.** *Proceedings of the National Academy of Sciences of the United States of America*

  Doherty, M. R., Cheon, H. n., Junk, D. J., Vinayak, S. n., Varadan, V. n., Telli, M. L., Ford, J. M., Stark, G. R., Jackson, M. W.

  2017; 114 (52): 13792–97

- **Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC)**

  Meric-Bernstam, F., Tannir, N., Harding, J., Voss, M., Mier, J., DeMichele, A., Munster, P., Patel, M., Iliopoulos, O., Owonikoko, T., Whiting, S., Orford, K., Bennett, et al

  ELSEVIER SCI LTD.2016: S12–S13

- **A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.** *Future oncology*

  Isakoff, S. J., Puhalla, S., Domchek, S. M., Friedlander, M., Kaufman, B., Robson, M., Telli, M. L., Diéras, V., Han, H. S., Garber, J. E., Johnson, E. F., Maag, D., Qin, et al

  2016: -?

- **Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.** *Annals of surgical oncology*

  Tsai, J., Bertoni, D., Hernandez-Boussard, T., Telli, M. L., Wapnir, I. L.

  2016; 23 (10): 3310-3316

- **Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial**

  Balmana, J., Cruz, C., Arun, B. K., Telli, M., Garber, J., Domchek, S., Fernandez, C. M., Kahatt, C., Szyldergemajn, S., Soto-Matos, A., Perez de la Haza, A., Perez Fidalgo, J. A., Lluch-Hernandez, et al

  OXFORD UNIV PRESS.2016

- **Genetics of triple-negative breast cancer: Implications for patient care.** *Current problems in cancer*

  Afghahi, A., Telli, M. L., Kurian, A. W.

  2016; 40 (2-4): 130-140

- **Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.** *Journal of oncology practice / American Society of Clinical Oncology*

  Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., Hofmann, L. V., Neal, J. W., Telli, M. L.

  2016; 12 (8): 763-764

- **Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline** *JOURNAL OF CLINICAL ONCOLOGY*

  Denduluri, N., Somerfield, M. R., Eisen, A., Holloway, J. N., Hurria, A., King, T. A., Lyman, G. H., Partridge, A. H., Telli, M. L., Trudeau, M. E., Wolff, A. C.

  2016; 34 (20): 2416-U186

- **Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)**
  Meric-Bernstam, F., Tannir, N. M., Mier, J., DeMichele, A., Telli, M. L., Fan, A. C., Munster, P. N., Carvajal, R. D., Orford, K. W., Bennett, M. K., Iliopoulos, O., Owonikoko, T., Patel, et al
  AMER SOC CLINICAL ONCOLOGY.2016

- **Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).**
  DeMichele, A., Harding, J. J., Telli, M. L., Munster, P. N., McKay, R., Iliopoulos, O., Orford, K. W., Bennett, M. K., Mier, J., Owonikoko, T., Patel, M. R., Carvajal, R. D., Meric-Bernstam, et al
  AMER SOC CLINICAL ONCOLOGY.2016

- **Invasive Breast Cancer Version 1.2016 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., Goetz, M., Goldstein, L. J., Hudis, et al
  2016; 14 (3): 324-354

- **Genetics of triple-negative breast cancer: Implications for patient care** *CURRENT PROBLEMS IN CANCER*
  Afghahi, A., Telli, M. L., Kurian, A. W.
  2016; 40 (2-4): 130-140

- **Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis**
  Telli, M. L., McMillan, A., Ford, J. M., Richardson, A. L., Silver, D. P., Isakoff, S. J., Kaklamani, V. G., Gradishar, W., Stearns, V., Connolly, R. M., Loibl, S., Elkin, E. P., Timms, et al
  AMER ASSOC CANCER RESEARCH.2016

- **The Talazoparib Beyond BRCA (TBB) trial: A phase II clinical trial of talazoparib (BMN 673) in BRCA1 and BRCA2 wild-type patients with (i) advanced triple negative breast cancer (TNBC) and homologous recombination deficiency (HRD) as assessed by myriad genetics HRD assay, and (ii) advanced HER2-negative breast cancer (BC) with either a germline or somatic mutation in homologous recombination (HR) pathway genes**
  Afghahi, A., Chang, P., Ford, J. M., Telli, M. L.
  AMER ASSOC CANCER RESEARCH.2016

- **ABRAZO: An international phase 2 (2-stage, 2-cohort) study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer**
  Turner, N. C., Balmana, J., Fasching, P. A., Hurvitz, S. A., Rugo, H. S., Telli, M. L., Visco, F., Wardley, A. M., Yang, X., Lokker, N. A., Lounsbury, D. L., Robson, M. E.
  AMER ASSOC CANCER RESEARCH.2016

- **Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis**
  Telli, M. L., McMillan, A., Ford, J. M., Richardson, A. L., Silver, D. P., Isakoff, S. J., Kaklamani, V. G., Gradishar, W., Stearns, V., Connolly, R. M., Loibl, S., Elkin, E. P., Timms, et al
  AMER ASSOC CANCER RESEARCH.2016

- **Breast Cancer After Hodgkin Lymphoma: The Price of Success.** *Oncology (Williston Park, N.Y.)*
  Manzo, V. n., Dirbas, F. n., Telli, M. L.
  2016; 30 (12)

- **Breast Cancer, Version 1.2016.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., Goetz, M., Goldstein, L. J., Hudis, et al
  2015; 13 (12): 1475-85

- **Breast Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., Goetz, M., Goldstein, L. J., Hudis, et al
  2015; 13 (12): 1475-1485

- **Synergy of LCL161, an antagonist of inhibitor of apoptosis proteins (IAPs), with paclitaxel in a gene expression signature-enriched cohort of triple-negative breast cancer (TNBC)**

  Bardia, A., Cameron, J. S., Venkatesan, K., Robinson, D., Porter, D., Kim, S. B., Parton, M., Kuemmel, S., Estevez, L. G., Huang, C. S., Cortes Castan, J., Ruiz-Borrego, M., Telli, et al

  ELSEVIER SCI LTD.2015: S326

- **Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105** *JOURNAL OF CLINICAL ONCOLOGY*

  Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., Timms, K., Abkevich, V., Schackmann, E. A., Wapnir, I. L., Carlson, R. W., Chang, P., Sparano, et al

  2015; 33 (17): 1895-U57

- **Association of tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based therapy in breast cancer (BC) with therapy resistance.**

  Afghahi, A., Timms, K., Vinayak, S., Jensen, K. C., Chang, P., Hartman, A., Ford, J. M., Telli, M. L.

  AMER SOC CLINICAL ONCOLOGY.2015

- **Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.**

  Harding, J. J., Telli, M. L., Munster, P. N., Le, M. H., Molineaux, C., Bennett, M. K., Mittra, E., Burris, H. A., Clark, A., Dunphy, M., Meric-Bernstam, F., Patel, M. R., DeMichele, et al

  AMER SOC CLINICAL ONCOLOGY.2015

- **Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer**

  Telli, M. L., Timms, K., Reid, J. E., Neff, C., Abkevich, V., Gutin, A., Sangale, Z., Illiev, D., Jones, J., Hennessy, B., Lanchbury, J. S., Mills, G. B., Hartman, et al

  AMER SOC CLINICAL ONCOLOGY.2015

- **Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.**

  Harding, J. J., Telli, M. L., Munster, P. N., Le, M. H., Molineaux, C., Bennett, M. K., Mittra, E., Burris, H. A., Clark, A., Dunphy, M., Meric-Bernstam, F., Patel, M. R., DeMichele, et al

  AMER SOC CLINICAL ONCOLOGY.2015

- **Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer**

  Telli, M. L., Timms, K., Reid, J. E., Neff, C., Abkevich, V., Gutin, A., Sangale, Z., Illiev, D., Jones, J., Hennessy, B., Lanchbury, J. S., Mills, G. B., Hartman, et al

  AMER SOC CLINICAL ONCOLOGY.2015

- **Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers** *CANCER DISCOVERY*

  Watkins, J., Weekes, D., Shah, V., Gazinska, P., Joshi, S., Sidhu, B., Gillett, C., Pinder, S., Vanoli, F., Jasin, M., Mayrhofer, M., Isaksson, A., Cheang, et al

  2015; 5 (5): 488-505

- **Homologous recombination deficiency (HRD) score predicts response to standard neoadjuvant chemotherapy in patients with triple negative or BRCA1/2 mutation-associated breast cancer**

  Telli, M. L., Audeh, W., Jensen, K. C., Bose, S., Timms, K., Gutin, A., Abkevich, V., Lanchbury, J., Neff, C., Hughes, E., Sangale, Z., Jones, J., Wenstrup, et al

  AMER ASSOC CANCER RESEARCH.2015

- **Deconvoluting immune cell populations using 'in silico flow cytometry' with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC**

  Vinayak, S., Newman, A., Adams, S., Afghahi, A., Jensen, K. C., Badve, S. S., Ford, J. M., Alizadeh, A. A., Telli, M. L.

  AMER ASSOC CANCER RESEARCH.2015

- **Evolving treatment strategies for triple-negative breast cancer.** *Journal of the National Comprehensive Cancer Network*

  Telli, M.

  2015; 13 (5): 652-654

- **Breast Cancer Version 2.2015** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., Goetz, M., Goldstein, L. J., Hudis, et al
  2015; 13 (4): 448-475

- **The future of breast cancer systemic therapy: the next 10 years.** *Journal of molecular medicine (Berlin, Germany)*
  Telli, M. L., Sledge, G. W.
  2015; 93 (2): 119-125

- **(18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.** *Radiology*
  Iagaru, A., Mosci, C., Shen, B., Chin, F. T., Mittra, E., Telli, M. L., Gambhir, S. S.
  2014; 273 (2): 549-559

- **F-18-FPPRGD2 PET/CT: Pilot Phase Evaluation of Breast Cancer Patients** *RADIOLOGY*
  Lagaru, A., Mosci, C., Shen, B., Chin, F. T., Mittra, E., Telli, M. L., Gambhir, S. S.
  2014; 273 (2): 549-559

- **Genotype discordance between circulating tumor cells in blood and disseminated tumor cells in bone marrow at single cell level in breast cancer patients**
  Deng, G., Krishnakumar, S., Coram, M. A., Powell, A. A., Zhang, H., Mindrinos, M. N., Telli, M. L., Effenberger, K. E., Herrler, M., Pantel, K., Davis, R. W., Jeffrey, S. S.
  AMER ASSOC CANCER RESEARCH.2014

- **Multi-omic profiling to predict response to gemcitabine/ carboplatin (GC) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer using a pathway-based approach**
  Vinayak, S., Benz, S. C., Vaske, C. J., Telli, M. L., Ford, J. M.
  AMER ASSOC CANCER RESEARCH.2014

- **Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow** *BMC CANCER*
  Deng, G., Krishnakumar, S., Powell, A. A., Zhang, H., Mindrinos, M. N., Telli, M. L., Davis, R. W., Jeffrey, S. S.
  2014; 14

- **Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.**
  Vinayak, S., Gray, R., Adams, S., Jensen, K. C., Manola, J., Afghahi, A., Goldstein, L. J., Ford, J. M., Badve, S. S., Telli, M. L.
  AMER SOC CLINICAL ONCOLOGY.2014

- **Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.** *Breast cancer research*
  Zhang, H., Cohen, A. L., Krishnakumar, S., Wapnir, I. L., Veeriah, S., Deng, G., Coram, M. A., Piskun, C. M., Longacre, T. A., Herrler, M., Frimannsson, D. O., Telli, M. L., Dirbas, et al
  2014; 16 (2): R36-?

- **The role of platinum therapy in triple-negative breast cancer** *The role of platinum therapy in triple-negative breast cancer*
  Afghahi, A., Telli, M. L.
  2014; 3 (4): 377-385

- **Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition** *BREAST CANCER RESEARCH*
  Zhang, H., Cohen, A. L., Krishnakumar, S., Wapnir, I. L., Veeriah, S., Deng, G., Coram, M. A., Piskun, C. M., Longacre, T. A., Herrler, M., Frimannsson, D. O., Telli, M. L., Dirbas, et al
  2014; 16 (2)

- **The role of platinum therapy in triple-negative breast cancer** *Breast Cancer Management*
  Afghahi, A., Telli, M. L.
  2014; 3 (4): 377-385

- **Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.** *American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting*
  Telli, M.

2014; 34: e37-42

- **Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.** *BMC cancer*
  Deng, G., Krishnakumar, S., Powell, A. A., Zhang, H., Mindrinos, M. N., Telli, M. L., Davis, R. W., Jeffrey, S. S.
  2014; 14: 456-?

- **Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.** *Journal of the American Medical Informatics Association*
  Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., Rubin, D. L.
  2013; 20 (6): 1059-1066

- **A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.** *Breast cancer research and treatment*
  Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, E., McPherson, L., Fernandez, A. M., Sharma, V. B., Staton, A., Mills, M. A., Schackmann, E. A., Telli, M. L., Kardashian, et al
  2013; 142 (2): 389-398

- **Insight or Confusion: Survival After Response-Guided Neoadjuvant Chemotherapy in Breast Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
  Telli, M. L.
  2013; 31 (29): 3613-3615

- **PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer**
  Telli, M. L., Jensen, K. C., Kurian, A. W., Vinayak, S., Lipson, J. A., Schackmann, E. A., Wapnir, I., Carlson, R. W., Sparano, J. A., Head, B., Goldstein, L. J., Haley, B. B., Dakhil, et al
  AMER SOC CLINICAL ONCOLOGY.2013

- **A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk** *BREAST CANCER RESEARCH AND TREATMENT*
  Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, B., McPherson, L., Fernandez, A. M., Sharma, V. B., Staton, A., Mills, M. A., Schackmann, E. A., Telli, M. L., Kardashian, et al
  2013; electronic publication ahead of print, October 30

- **Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer.** *AMIA Summits on Translational Science proceedings AMIA Summit on Translational Science*
  Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., Rubin, D. L.
  2013; 2013: 62-?

- **Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer.** *Nature and science of sleep*
  Palesh, O., Peppone, L., Innominato, P. F., Janelsins, M., Jeong, M., Sprod, L., Savard, J., Rotatori, M., Kesler, S., Telli, M., Mustian, K.
  2012; 4: 151-162

- **Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple negative and BRCA1/2 mutation-associated breast cancer (BC)**
  Telli, M. L., Jensen, K. C., Abkevich, V., Hartman, A., Vinayak, S., Lanchbury, J., Gutin, A., Timms, K., Ford, J. M.
  AMER ASSOC CANCER RESEARCH.2012

- **Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., Ganjoo, K., Lebensohn, A., Ford, J. M., Telli, M. L.
  2012; 10 (8): 939-942

- **Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort** *BREAST CANCER RESEARCH AND TREATMENT*
  Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., Balmana, J., Gruber, S. B., Ford, J. M., Euhus, D., Lebensohn, A., Telli, M., Pochebit, S. M., Lypas, et al
  2012; 133 (3): 1125-1130

- **Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?** *JOURNAL OF CLINICAL ONCOLOGY*
  Witteles, R. M., Telli, M.
  2012; 30 (16): 1916-1918

- **Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines** *PLOS ONE*
  Powell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., Telli, M. L., Advani, R. H., Carlson, R. W., Mollick, J. A., Sheth, S., Kurian, A. W., Ford, et al
  2012; 7 (5)

- **Breast Cancer Heterogeneity and Treatment Resistance: Clues from Metaplastic Tumors**
  Felding-Habermann, B., O'Sullivan, D. M., Lorger, M., MacDermed, D., Fernandez-Santidrian, A., Steele, J. B., Telli, M. L., Jeffrey, S. S., Murray, S., Torkamani, A., Cunliffe, H., Vaughn, S. V.
  AMER ASSOC CANCER RESEARCH.2011

- **A Phase II Study of Gemcitabine and Carboplatin (GC) Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer.**
  Telli, M. L., Kurian, A. W., Jensen, K. C., Vinayak, S., Flaherty, P., Lipson, J. A., Wapnir, I., Daniel, B., Carlson, R. W., Mills, M. A., Chang, P., Schackmann, E., Rocha, et al
  AMER ASSOC CANCER RESEARCH.2011

- **Utilizing BRCA1/2 mutation status to select patients for breast cancer clinical trials: Expetience from a prospective phase II trial**
  Schackmann, E. A., Vinayak, S., Kurian, A. W., Ford, J. M., Telli, M. L.
  AMER SOC CLINICAL ONCOLOGY.2011

- **Phase 3 Study of Iniparib (I) Plus Gemcitabine (G) and Carboplatin (C) in Metastatic Triple-negative Breast Cancer (mTNBC) - Results of an Exploratory Analysis by Prior Therapy**
  O'Shaughnessy, J., Telli, M., Swain, S., Gralow, J., Rugo, H., Litton, J., Charpentier, E., Smith, J., Blackwood-Chirchir, A., Winer, E.
  ELSEVIER SCI LTD.2011: S338

- **Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?** *HEART FAILURE CLINICS*
  Witteles, R. M., Fowler, M. B., Telli, M. L.
  2011; 7 (3): 333-?

- **Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry** *BREAST CANCER RESEARCH AND TREATMENT*
  Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H., McClure, L. A., Lichtensztajn, D., Ford, J. M., Gomez, S. L.
  2011; 127 (2): 471-478

- **18F FPPRGD2 in breast cancer subjects: A novel PET radiopharmaceutical for imaging alpha v beta 3 integrin levels**
  Iagaru, A., Mosci, C., Mittra, E., Shen, B., Chin, F., Chen, X., Telli, M., Gambhir, S.
  SOC NUCLEAR MEDICINE INC.2011

- **Treating Asymptomatic Chemotherapy-Induced Cardiac Dysfunction A Chance That Cardiologists and Oncologists Should Not Miss Reply** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
  Witteles, R. M., Yoon, G., Telli, M., Kao, D. P., Matsuda, K. Y., Carlson, R. W.
  2011; 57 (17): 1790-1791

- **Trastuzumab-Related Cardiac Dysfunction** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Telli, M. L., Witteles, R. M.
  2011; 9 (2): 243-249

- **Assessment of Extent of Disease in Primary Breast Cancer** *BREAST SURGICAL TECHNIQUES AND INTERDISCIPLINARY MANAGEMENT*
  Telli, M. L., Guardino, A. E.
  edited by Dirbas, F. M., ScottConner, C. E.
  2011: 263-268

- **DNA Mutation as a Biomarker for Tracking Circulating Tumor Cells and Disseminated Tumor Cells in Breast Cancer Metastases**
  Deng, G., Powell, A. A., Zhang, H., Krishnakumar, S., Telli, M. L., Herrler, M., Mindrinos, M., Davis, R. W., Jeffrey, S. S.
  AMER ASSOC CANCER RESEARCH.2010

- **Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally?** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
  Yoon, G. J., Telli, M. L., Kao, D. P., Matsuda, K. Y., Carlson, R. W., Witteles, R. M.
  2010; 56 (20): 1644-1650

- **PARP inhibitors in breast cancer.** *Clinical advances in hematology & oncology : H&O*
  Telli, M. L., Ford, J. M.
  2010; 8 (9): 629-635
- **Novel Treatment Approaches for Triple-Negative Breast Cancer** *CLINICAL BREAST CANCER*
  Telli, M. L., Ford, J. M.
  2010; 10: E16-E22
- **Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California** *JOURNAL OF CLINICAL ONCOLOGY*
  Gomez, S. L., Lichtensztajn, D., Kurian, A. W., Telli, M. L., Chang, E. T., Keegan, T. H., Glaser, S. L., Clarke, C. A.
  2010; 28 (10): E155-E157
- **Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls** *CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION*
  Gramatges, M. M., Telli, M. L., Balise, R., Ford, J. M.
  2010; 19 (2): 605-613
- **First-Line Chemotherapy for Metastatic Breast Cancer** *CLINICAL BREAST CANCER*
  Telli, M. L., Carlson, R. W.
  2009; 9: S66-S72
- **Prospective cardiotoxicity screening during tyrosine kinase inhibitor therapy for renal cell carcinoma: An institutional experience**
  Witteles, R. M., Harshman, L. C., Telli, M., Srinivas, S.
  AMER SOC CLINICAL ONCOLOGY.2009
- **Telomere length shortening in individuals with sporadic compared with familial breast cancer**
  Gramatges, M., Telli, M., Balise, R., Ford, J.
  AMER ASSOC CANCER RESEARCH.2009
- **Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate** *ANNALS OF ONCOLOGY*
  Telli, M. L., Witteles, R. M., Fisher, G. A., Srinivas, S.
  2008; 19 (9): 1613-1618
- **Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility** *JOURNAL OF CLINICAL ONCOLOGY*
  Telli, M. L., Hunt, S. A., Carlson, R. W., Guardino, A. E.
  2007; 25 (23): 3525-3533
- **Phyllodes tumors of the breast: natural history, diagnosis, and treatment.** *Journal of the National Comprehensive Cancer Network*
  Telli, M. L., Horst, K. C., Guardino, A. E., Dirbas, F. M., Carlson, R. W.
  2007; 5 (3): 324-330
- **Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells** *BIOCHEMICAL PHARMACOLOGY*
  Yang, L. J., Guo, Y. L., Trygankova, O., Li, Q. Y., Maloney, J. A., Steinhauer, M., Williamson, J. R.
  1999; 57 (4): 425-432
- **Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells** *BIOCHEMICAL PHARMACOLOGY*
  Yang, L. J., Guo, Y. L., Trygankova, O., Li, Q. Y., Maloney, J. A., Steinhauer, M., Williamson
  1999; 57 (4): 425-432